News and Announcements

AstraZeneca lifts lung‑cancer pipeline with Zegfrovy deal, Tagrisso data

By Iain Gilbert

Date: Tuesday 01 Sep 2026

(Sharecast News) - Drugmaker Astrazeneca delivered a pair of lung‑cancer updates on Tuesday, with the group completing a global licensing deal for Zegfrovy (sunvozertinib) while also reporting positive Phase III data for a Tagrisso-Orpathys combination in first‑line MET‑overexpressing EGFR‑mutated disease.
Astrazeneca said it has now finalised its exclusive agreement with Dizal...

Sign up for free or to read the full story

Email this article to a friend

or share it with one of these popular networks:


Article Archive

Top of Page